Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 4/2015

01.12.2015 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM

verfasst von: Naveen Pemmaraju, Vikas Gupta, Ruben Mesa, Michael A. Thompson

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the field of hematology and oncology, a field which frequently experiences rapid shifts of information and novel, practice-changing discoveries. Among the many social media platforms available to cancer patients and providers, one platform in particular, Twitter, has become the focus for the creation of disease-specific communities, especially for those interested in, affected by, or those who perform research in the fields of rare cancers, which historically have had a dearth of reliable information available. This article will focus on the initiation and progress of one such Twitter hematology/oncology community, #mpnsm, which was originally created for the purpose of serving as a venue for improving the interaction among patients, providers, researchers, and organizations with interest in the myeloproliferative neoplasms (MPNs) and to further the availability of reliable up-to-date analysis; relevant expert commentary; and readily usable information for patients, providers, and other groups interested in this field.
Literatur
2.
Zurück zum Zitat Baptist AP, Thompson M, Grossman KS, Mohammed L, Sy A, Sanders GM. Social media, text messaging, and email-preferences of asthma patients between 12 and 40 years old. J Asthma. 2011;48:824–30.CrossRefPubMed Baptist AP, Thompson M, Grossman KS, Mohammed L, Sy A, Sanders GM. Social media, text messaging, and email-preferences of asthma patients between 12 and 40 years old. J Asthma. 2011;48:824–30.CrossRefPubMed
3.
Zurück zum Zitat Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782, 4–5–91. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26:782, 4–5–91.
4.
Zurück zum Zitat Hawn C. Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care. Health Aff. 2009;28:361–8.CrossRef Hawn C. Take two aspirin and tweet me in the morning: how Twitter, Facebook, and other social media are reshaping health care. Health Aff. 2009;28:361–8.CrossRef
5.
Zurück zum Zitat Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: twitter and antibiotics. Am J Infect Control. 2010;38:182–8.PubMedCentralCrossRefPubMed Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: twitter and antibiotics. Am J Infect Control. 2010;38:182–8.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17:e188.CrossRefPubMed Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17:e188.CrossRefPubMed
7.
8.
Zurück zum Zitat Lazard AJ, Scheinfeld E, Bernhardt JM, Wilcox GB, Suran M. Detecting themes of public concern: a text mining analysis of the centers for disease control and prevention’s Ebola live Twitter chat. Am J Infect Control. 2015;doi: 10.1016/j.ajic.2015.05.025. Lazard AJ, Scheinfeld E, Bernhardt JM, Wilcox GB, Suran M. Detecting themes of public concern: a text mining analysis of the centers for disease control and prevention’s Ebola live Twitter chat. Am J Infect Control. 2015;doi: 10.​1016/​j.​ajic.​2015.​05.​025.
9.
Zurück zum Zitat Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J Oncol Pract. 2012;8:173–8.PubMedCentralCrossRefPubMed Chaudhry A, Glode LM, Gillman M, Miller RS. Trends in twitter use by physicians at the American Society of Clinical Oncology annual meeting, 2010 and 2011. J Oncol Pract. 2012;8:173–8.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Nwosu AC, Debattista M, Rooney C, Mason S. Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life. BMJ Support Palliat Care. 2015;5:207–12.CrossRefPubMed Nwosu AC, Debattista M, Rooney C, Mason S. Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life. BMJ Support Palliat Care. 2015;5:207–12.CrossRefPubMed
11.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
12.
Zurück zum Zitat Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed
13.
Zurück zum Zitat O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.CrossRefPubMed O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.CrossRefPubMed
14.
Zurück zum Zitat Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.PubMedCentralCrossRefPubMed Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-Positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.CrossRef Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-Positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.CrossRef
16.
Zurück zum Zitat Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed
17.
Zurück zum Zitat Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.CrossRefPubMed Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.CrossRefPubMed
18.
Zurück zum Zitat Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed
19.
Zurück zum Zitat Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed
20.
Zurück zum Zitat Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.PubMedCentralCrossRefPubMed Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMed
23.
Zurück zum Zitat Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–901.CrossRefPubMed Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–901.CrossRefPubMed
24.
Zurück zum Zitat Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefPubMed Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.CrossRefPubMed
25.
Zurück zum Zitat Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.CrossRefPubMed Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.CrossRefPubMed
26.
Zurück zum Zitat Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.CrossRefPubMed Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.CrossRefPubMed
27.
Zurück zum Zitat Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529–37.CrossRefPubMed Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124:3529–37.CrossRefPubMed
28.
Zurück zum Zitat Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.CrossRefPubMed Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.CrossRefPubMed
29.
Zurück zum Zitat Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMed Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMed
30.
Zurück zum Zitat Cartledge P, Miller M, Phillips B. The use of social-networking sites in medical education. Med Teach. 2013;35:847–57.CrossRefPubMed Cartledge P, Miller M, Phillips B. The use of social-networking sites in medical education. Med Teach. 2013;35:847–57.CrossRefPubMed
31.
Zurück zum Zitat McGowan BS, Wasko M, Vartabedian BS, Miller RS, Freiherr DD, Abdolrasulnia M. Understanding the factors that influence the adoption and meaningful use of social media by physicians to share medical information. J Med Internet Res. 2012;14:e117.PubMedCentralCrossRefPubMed McGowan BS, Wasko M, Vartabedian BS, Miller RS, Freiherr DD, Abdolrasulnia M. Understanding the factors that influence the adoption and meaningful use of social media by physicians to share medical information. J Med Internet Res. 2012;14:e117.PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Wilkinson SE, Basto MY, Perovic G, Lawrentschuk N, Murphy DG. The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int. 2015;115:839–46.CrossRefPubMed Wilkinson SE, Basto MY, Perovic G, Lawrentschuk N, Murphy DG. The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int. 2015;115:839–46.CrossRefPubMed
33.
Zurück zum Zitat Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:suppl abstr 6520. Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:suppl abstr 6520.
34.
Zurück zum Zitat Bahkali S, Almaiman A, Bahkali A, Almaiman S, Househ M, Alsurimi K. The role of social media in promoting women’s health education in Saudi Arabia. Stud Health Technol Inform. 2015;213:259–62.PubMed Bahkali S, Almaiman A, Bahkali A, Almaiman S, Househ M, Alsurimi K. The role of social media in promoting women’s health education in Saudi Arabia. Stud Health Technol Inform. 2015;213:259–62.PubMed
35.
36.
37.
Zurück zum Zitat Kitching F, Winbolt M, MacPhail A, Ibrahim JE. Web-based social media for professional medical education: perspectives of senior stakeholders in the nursing home sector. Nurse Educ Today. 2015; doi:10.1016/j.nedt.2015.05.013. Kitching F, Winbolt M, MacPhail A, Ibrahim JE. Web-based social media for professional medical education: perspectives of senior stakeholders in the nursing home sector. Nurse Educ Today. 2015; doi:10.​1016/​j.​nedt.​2015.​05.​013.
38.
Zurück zum Zitat Jalali A, Sherbino J, Frank J, Sutherland S. Social media and medical education: exploring the potential of Twitter as a learning tool. Int Rev Psychiatry. 2015;27:140–6.CrossRefPubMed Jalali A, Sherbino J, Frank J, Sutherland S. Social media and medical education: exploring the potential of Twitter as a learning tool. Int Rev Psychiatry. 2015;27:140–6.CrossRefPubMed
39.
Zurück zum Zitat Chan TM, Thoma B, Lin M. Creating, curating, and sharing online faculty development resources: the medical education in cases series experience. Acad Med. 2015;90:785–9.CrossRefPubMed Chan TM, Thoma B, Lin M. Creating, curating, and sharing online faculty development resources: the medical education in cases series experience. Acad Med. 2015;90:785–9.CrossRefPubMed
41.
Zurück zum Zitat Bell JA, Balneaves LG. Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer. 2015;23:1169–96.CrossRefPubMed Bell JA, Balneaves LG. Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer. 2015;23:1169–96.CrossRefPubMed
42.
Zurück zum Zitat Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015; doi:10.1002/ajh.24098. Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015; doi:10.​1002/​ajh.​24098.
43.
Zurück zum Zitat Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56:1989–99.CrossRefPubMed Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56:1989–99.CrossRefPubMed
44.
Zurück zum Zitat Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep. 2014;9:324–30.CrossRefPubMed Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep. 2014;9:324–30.CrossRefPubMed
45.
Zurück zum Zitat Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781–90.PubMedCentralCrossRefPubMed Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781–90.PubMedCentralCrossRefPubMed
46.
47.
Zurück zum Zitat Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27:1852–60.CrossRefPubMed Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27:1852–60.CrossRefPubMed
48.
Zurück zum Zitat Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125:499–503.CrossRefPubMed Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125:499–503.CrossRefPubMed
49.
Zurück zum Zitat Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649–55.PubMedCentralCrossRefPubMed Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649–55.PubMedCentralCrossRefPubMed
50.
Zurück zum Zitat Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.PubMedCentralCrossRefPubMed Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.PubMedCentralCrossRefPubMed
51.
Zurück zum Zitat Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–19.CrossRefPubMed Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–19.CrossRefPubMed
52.
Zurück zum Zitat Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–8.CrossRefPubMed Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–8.CrossRefPubMed
53.
Zurück zum Zitat Armanios M, Greider CW. Treating myeloproliferation—on target or off? N Engl J Med. 2015;373:965–6.CrossRefPubMed Armanios M, Greider CW. Treating myeloproliferation—on target or off? N Engl J Med. 2015;373:965–6.CrossRefPubMed
54.
Metadaten
Titel
Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM
verfasst von
Naveen Pemmaraju
Vikas Gupta
Ruben Mesa
Michael A. Thompson
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2015
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-015-0287-9

Weitere Artikel der Ausgabe 4/2015

Current Hematologic Malignancy Reports 4/2015 Zur Ausgabe

Multiple Myeloma (R Nievszky, Section Editor)

Novel Induction Regimens in Multiple Myeloma

Myeloproliferative Disorders (C Harrison, Section Editor)

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis

Myeloproliferative Disorders (C Harrison, Section Editor)

Current Challenges in Stem Cell Transplantation in Myelofibrosis

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.